Clinical Trial Update: Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of niraparib as neoadjuvant therapy for unresectable ovarian cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING